Atlas Trials

DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

Clinical trial NCT04963231 · COMPLETED

Trial details

NCT number
NCT04963231
Sponsor
Rhythm Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Genetic Obesity
Start date
2021-11-30
Primary completion
2023-08-04
Enrollment
164

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.